Humacyte, Inc. logo HUMA - Humacyte, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 10
HOLD 1
SELL 0
STRONG
SELL 0
| PRICE TARGET: $3.00 DETAILS
HIGH: $3.00
LOW: $3.00
MEDIAN: $3.00
CONSENSUS: $3.00
UPSIDE: 185.71%

Stock News

Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals – - SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the approval process by individual hospitals - DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess is now under contract with the with Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs (VA).

May 20, 2026 04:00 AM • globenewswire.com
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer -  - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Announced Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess for Vascular Injury Repair - - U.S. Department of Defense funding for procurement of bioengineered blood vessels - - Major milestone upcoming: Top-line interim results from V012 Phase 3 study in hemodialysis access - -Conference call today at 8:00 am ET - DURHAM, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.

May 13, 2026 03:00 AM • globenewswire.com
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”).On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engi.

May 08, 2026 02:00 PM • businesswire.com
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter ended March 31, 2026 on Wednesday, May 13, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.

May 08, 2026 04:00 AM • globenewswire.com
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, April 28, 2026 at 8:00 AM ET featuring Prabir Roy-Chaudhury MD, PhD, FASN (University of North Carolina (UNC) Kidney Center, Salisbury VA Medical Center), and Mohamad A.

Apr 27, 2026 04:00 AM • globenewswire.com
Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

- Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care -  - Positions Humacyte to advance discussions with corporate partners regarding international and indication-specific rights to Symvess – - Existing terms related to U.S. distribution of Symvess remain unchanged DURHAM, N.C., April 24, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has realigned the ex-U.S. rights to Symvess (acellular tissue engineered vessel) through an amendment to its distribution agreement with Fresenius Medical Care (FME).

Apr 24, 2026 04:00 AM • globenewswire.com
Humacyte Appoints Jim Mercadante as Chief Commercial Officer

Humacyte Appoints Jim Mercadante as Chief Commercial Officer

– Industry veteran with more than 25 years of experience will lead next phase of biotech company's commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success in vascular and cardiothoracic surgery markets – – Appointment strengthens commercial leadership as Symvess® (acellular tissue engineered vessel-tyod) market launch accelerates and pipeline advances toward planned BLA filing in dialysis – DURHAM, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the appointment of Jim Mercadante as Chief Commercial Officer.

Apr 22, 2026 04:00 AM • globenewswire.com
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

- The Ministry of Health has set a 180-working-day review period for the MAA -  - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that its Marketing Authorization Application (MAA) seeking approval of the acellular tissue engineered vessel (ATEV, or Symvess) for arterial trauma repair has been accepted by the Israel Ministry of Health.

Apr 21, 2026 04:00 AM • globenewswire.com
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”). On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tiss.

Apr 13, 2026 09:21 AM • businesswire.com

Price Targets